Search clinical trials for: CardioMEMS HF System

Total 78273 results

Assistance Publique - Hôpitaux de Paris
Ministry of Health, France; Baxter Healthcare Corporation; Amgen

Completed

High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II

Testicular Neoplasms

France
Inje University

Unknown

BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL)

Non Hodgkin's Lymphoma

Korea, Republic of
M.D. Anderson Cancer Center
Bayer

Terminated

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

Lymphoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia | Advanced Myelodysplastic Syndromes

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Refractory Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma

United States
University Hospital Ostrava

Not yet recruiting

Determination of Drug Levels for Pharmacotherapy of Heart Failure

Cardiovascular Diseases | Heart Failure With Reduced Ejection Fraction

Czechia
Emory University
National Cancer Institute (NCI)

Recruiting

Radiosurgery Before Surgery for the Treatment of Brain Metastases

Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Brain

United States
Multiple Myeloma Research Consortium
Eli Lilly and Company; GlaxoSmithKline; AbbVie; Takeda; Genentech, Inc.; Celgene Corporation and other collaborators

Recruiting

Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG)

Relapsed Refractory Multiple Myeloma

United States
University of California, San Francisco
Janssen Pharmaceuticals; Multiple Myeloma Research Foundation

Terminated

Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma

United States
Mayo Clinic
Multiple Myeloma Research Foundation

Completed

Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma | t(11;14)

United States
Andrei Iagaru
General Electric

Completed

68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer

Breast Carcinoma | Estrogen Receptor Positive

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma | Loss of Chromosome 17p

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia

Leukemia

United States, Canada, Australia, Switzerland, Puerto Rico, Netherlands
Academic and Community Cancer Research United
National Cancer Institute (NCI); Janssen Scientific Affairs, LLC

Withdrawn

Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation

Recurrent Acute Myeloid Leukemia

United States
National Institute of Allergy and Infectious Diseases...

Completed

Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members

HIV Infections | Lymphoma, Non-Hodgkin

United States
Ohio State University Comprehensive Cancer Center
Celgene

Completed

HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma

United States
Therapeutic Advances in Childhood Leukemia Consortium

Terminated

Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)

Relapsed Acute Lymphoblastic Leukemia | Allergy to PEG e.Coli Asparaginase | Allergy to Native e.Coli Asparaginase

United States
Penn State University
University of North Carolina, Greensboro

Completed

Engineering an Online STI Prevention Program

Sexually Transmitted Diseases | Sexual Behavior | Alcohol Consumption

United States
Stanford University
National Cancer Institute (NCI)

Completed

Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

B-cell Adult Acute Lymphoblastic Leukemia (ALL) | Ph-positive Adult Acute Lymphoblastic Leukemia (ALL) | Recurrent Adult Acute Lymphoblastic Leukemia (ALL) | T-cell Adult Acute Lymphoblastic Leukemia (ALL)

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Completed

Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy

Nausea and Vomiting | Malignant Digestive System Neoplasm

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia

Leukemia

United States, Australia, Canada
National Institute of Allergy and Infectious Diseases...

Recruiting

Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide

Chronic Granulomatous Disease

United States
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC

Recruiting

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Hodgkin Lymphoma | Relapsed or Refractory Hodgkin Lymphoma

United States
University of Saskatchewan

Not yet recruiting

Conversion From Unresectable To Resectable Metastatic Colorectal Cancer. (CONVERSION)

Metastatic Colorectal Cancer
Hackensack Meridian Health
Millennium Pharmaceuticals, Inc.

Completed

Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT (Thal/Mel/Vel)

Multiple Myeloma

United States
M.D. Anderson Cancer Center

Completed

Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma

Lymphoma | Disorder Related to Bone Marrow Transplantation

United States
M.D. Anderson Cancer Center
Novartis

Completed

Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas

Lymphoma

United States
Washington University School of Medicine

Completed

Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin | Multiple Myeloma

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI)

Withdrawn

Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma

Lymphoma
Baylor College of Medicine

Completed

Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation

Kidney Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

Lymphoma

United States
National Cancer Institute (NCI)

Completed

Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer

Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
Institut Paoli-Calmettes

Completed

Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

France
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis

Chronic Myeloproliferative Disorders

United States, United Kingdom, France
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); Cancer and Leukemia Group B

Completed

Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma

Lymphoma
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors

Head and Neck Carcinoma | Oropharyngeal Carcinoma | Cranial Nerve Disorder

United States
National Cancer Institute (NCI)

Completed

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Anemia | Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
Pfizer

Completed

A Study to Learn About the Drug-drug Interactions of Sisunatovir in Healthy Adult Participants

Respiratory Syncytial Virus Infections

United Kingdom
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia

Lymphoma | Leukemia

United States
Eastern Cooperative Oncology Group

Terminated

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

Lymphoma

United States
University Hospital Schleswig-Holstein
Deutsche Krebshilfe e.V., Bonn (Germany)

Completed

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia

Leukemia

Israel, Germany, Italy, Australia, Austria, Czechia, Switzerland
Mayo Clinic
National Cancer Institute (NCI)

Completed

Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma

Plasma Cell Myeloma | Smoldering Plasma Cell Myeloma | Indolent Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant

Plasma Cell Myeloma

United States

Search clinical trials for: CardioMEMS HF System

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations